Brismar K, Sidén A, Werner S
J Endocrinol Invest. 1981 Oct-Dec;4(4):393-7. doi: 10.1007/BF03348301.
The effect of the dopamine agonist bromocriptine (5-40 mg/day) on cerebrospinal fluid proteins and amines was studied in 7 hyperprolactinemic patients, 4 with empty sella syndrome and 3 patients with pituitary adenoma. Small as well as high doses of bromocriptine depressed the endogenously formed dopamine, noradrenalin and adrenalin. Five patients initially exhibited changes consistent with slight to marked blood-cerebrospinal-fluid (CSF) barrier disturbances and 5 abnormal CSF-protein fractions. One CSF-protein fraction (isolelectric points (pI) approximately 5.3 pH-units) became more prominent during bromocriptine treatment. Analyses of his fraction indicated that it represented a transferrin component. It is stated that bromocriptine treatment besides affecting amine and trace metal metabolism also affects protein metabolism.
在7例高催乳素血症患者（4例空蝶鞍综合征患者和3例垂体腺瘤患者）中研究了多巴胺激动剂溴隐亭（5 - 40毫克/天）对脑脊液蛋白质和胺类的影响。小剂量和大剂量的溴隐亭均能抑制内源性生成的多巴胺、去甲肾上腺素和肾上腺素。5例患者最初表现出与轻微至明显的血脑脊髓液（CSF）屏障紊乱一致的变化以及5种异常的脑脊液蛋白质组分。一种脑脊液蛋白质组分（等电点（pI）约为5.3个pH单位）在溴隐亭治疗期间变得更加突出。对该组分的分析表明它代表一种转铁蛋白成分。据称，溴隐亭治疗除了影响胺类和微量元素代谢外，还影响蛋白质代谢。
